At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 32 enrolled
Drug / intervention
Erlotinib +1 moredrug
Likely dose
Erlotinib 150mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Stereotactic Radiosurgery or Other Local Ablation Followed by Erlotinib for Patients With Epidermal Growth Factor Receptor(EGFR) Mutation Who Have Previously Progressed on an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
In Brief
A Phase 2 clinical trial evaluating Stereotactic Radiosurgery and Erlotinib for Non Small Cell Lung Cancer. Completed, enrolled 32 participants across 8 sites.
Detailed Summary
\- Progression free survival after locally ablative therapy and erlotinib in EGFR patients progressed after EGFR-TKI therapy
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Small Cell Lung Cancer
CountriesUnited States
CollaboratorsAstellas Pharma Global Development, Inc.
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedApr 2012
Enrollment StartDec 2012
Primary CompletionMar 2019
TodayJul 2026
First PostedApr 9, 2012
Enrollment StartDec 11, 2012
Primary CompletionMar 15, 2019
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 14.2 years ago
Interventions
Stereotactic Radiosurgeryprocedure
21 Gy daily for 5 days
Erlotinibdrug
150mg once daily